Abstract
A single-nucleotide polymorphism (3'322C/G) was identified in the gene encoding a key cholesterol/triglyceride regulator, sterol-regulatory element-binding protein 1c (SREBP-1c). Although it did not alter the amino acid sequence, SREBP-1c-3'322C/G was predictive of highly active antiretroviral therapy-related hyperlipoproteinaemia. Increases in cholesterol were less frequently associated with homozygous SREBP-1c-3'322G (genotype 22) than with heterozygous/homozygous SREBP-1c-3'322C (genotypes 11/12) and correlated with leptin and insulin increases, particularly in genotype 11/12 carriers. A functional mutation linked to SREBP-1c-3'322C/G or messenger RNA conformation differences may explain our findings.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Apolipoproteins E / genetics
-
CCAAT-Enhancer-Binding Proteins / genetics*
-
CD4 Lymphocyte Count
-
Cohort Studies
-
DNA-Binding Proteins / genetics*
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV-1 / physiology
-
Humans
-
Hyperlipoproteinemias* / genetics
-
Polymorphism, Single Nucleotide / genetics*
-
Predictive Value of Tests
-
RNA, Viral / blood
-
Sterol Regulatory Element Binding Protein 1
-
Transcription Factors*
Substances
-
Apolipoproteins E
-
CCAAT-Enhancer-Binding Proteins
-
DNA-Binding Proteins
-
RNA, Viral
-
SREBF1 protein, human
-
Sterol Regulatory Element Binding Protein 1
-
Transcription Factors